Dihexa on TikTok: separating hype from actual human data

What did @simonwfitness actually say?

The creator described a self-experiment with dihexa, reporting that after four or five days of use at doses ranging up to around 500 micrograms, the effects felt like being "on top of the world" or severely anxious, with nothing in between. He called it a "nootropic" and compared the stimulation to taking DEXIs (dextroamphetamine). He then said he prefers semax for drive and selank for stress and anxiety, and described taking them separately or together depending on the day.

He did not cite a single study. He framed his personal experience as evidence, which is fine as far as anecdote goes, but he also gestured toward a product link in his bio, which moves this from personal update into promotional territory. That matters when you're talking about compounds that are not approved for human use.

Does the science back this up?

Partially, but the research base here is thin to nonexistent in humans, and the creator overstates confidence in all three compounds. Dihexa in particular has almost no human data at all. Semax and selank have more, but it's mostly Russian preclinical work.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University. McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) showed it potentiated HGF/MET signaling and improved cognition in aged rat models of Alzheimer's disease. That's it. There are no published human trials. The compound's potency in animal models is real, but extrapolating that to a human nootropic protocol is a long jump with no safety net.

Semax is a synthetic ACTH(4-7) analogue developed in Russia. Dolotov et al. (2006, Journal of Neurochemistry) showed it increases BDNF in rat hippocampus. Some small Russian clinical trials exist for ischemic stroke, but the quality of that data is limited. Selank is a tuftsin analogue with anxiolytic properties studied in Russian populations. Zozulya et al. (2001, Bulletin of Experimental Biology and Medicine) reported reduced anxiety in patients with generalized anxiety disorder. Neither compound has FDA approval or robust Phase III trial data in Western journals.

What did they get wrong (or right)?

He got the general character of each compound roughly right. Dihexa does appear to be a potent modulator of neuroplasticity mechanisms in animals. Semax is associated with dopaminergic and BDNF-related activation. Selank does have genuine anxiolytic data behind it. Calling it a "new tropic not as studied" as semax and selank is accurate. Credit where it's due.

What he got wrong is more important. He said he wanted to "spark" his cortisol with selank. That's backwards. Selank's proposed mechanism involves modulating rather than elevating stress hormones, and some research suggests it may reduce corticotropin-releasing hormone activity. Elevating cortisol is not the goal and not what the compound is thought to do.

More critically, describing dihexa as feeling like dextroamphetamine is anecdote, not pharmacology. Dihexa does not work through dopamine reuptake inhibition or catecholamine release. The comparison is experiential, not mechanistic, and could mislead viewers into expecting stimulant-type effects or, worse, stacking it with actual stimulants.

The dosing discussion is also a problem. He mentions 500 micrograms casually. There is no established safe or effective human dose for dihexa. Presenting personal dose exploration as a loose guide, even unintentionally, crosses a line when no human safety data exists.

What should you actually know?

These three compounds are research chemicals in most Western regulatory contexts. They are not FDA-approved. They are not legal to sell as supplements or drugs in the United States. They exist in a grey market where quality control varies significantly by vendor.

Dihexa specifically has zero published human pharmacokinetic data. You do not know its bioavailability, its half-life in humans, its metabolite profile, or its long-term effects on HGF/MET signaling, a pathway also implicated in certain cancers (Birchmeier et al., 2003, Nature Reviews Molecular Cell Biology). That is not a reason to panic, but it is a reason to be skeptical of anyone presenting it as a weekend nootropic stack.

Selank and semax have a longer history of human use in Russia and more actual clinical data, though the trial quality rarely meets Western standards. If you're curious about nootropic peptides, these two have a more defensible evidence base than dihexa, even if that base is still limited.

Anyone purchasing these compounds based on a TikTok video should know that neither FormBlends nor any responsible clinician can endorse sourcing research peptides from unregulated vendors. If you are interested in peptide therapy, that conversation belongs in a clinical setting with a licensed provider who can review your health history.